City Therapeutics to Present at Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in November.
Stifel 2026 Healthcare Conference
Fireside Chat: Tuesday, November 10, 2026, at 10:00 a.m. ET
Location: New York, New York
Jefferies Global Healthcare Conference in London
Presentation: Monday, November 16, 2026, at 1:00 p.m. GMT
Location: London, England
Live webcasts of the fireside chat and presentation will be available on the “News & Events” page within the Investors section of the City Therapeutics’ website at investors.citytx.com. A replay of the webcasts will be available for approximately 90 days.
About City Therapeutics
City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City’s lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection. For more information, visit www.citytx.com and follow us on LinkedIn, X, and Bluesky.
Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com
Investor Contact:
Stephanie Ascher, Precision AQ
Stephanie.Ascher@precisionaq.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
United States